Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies

Made Putra Semadhi, Stefanus Layli Prasojo, Anandani Widarini

Abstract


Lung cancer is the most contributor of cancer cause death in the world. Lung cancer is related to cigarette consumption and genetic factor. Nicotine derived nitrosamine ketone is the most important inducer of lung cancer associated with DNA Mutations resulting in the activation of Kirsten rat sarcoma viral (KRAS) oncogenes. DNA Mutation in Lung cancer is mostly presence by epidermal growth factor receptor (EGFR) mutations. There were seven potential biomarkers to detect early lung cancer, whereas carcinoembryonic antigen (CEA), neuron specific enolase (NSE), cytokeratin-19 fragments (CYFRA 21-1), alpha-fetoprotein (AFP), cancer antigen 125 (CA-125), CA-199 and ferritin. The use of biomarkers in combination can improve the accuracy in diagnosing lung cancer. Other biomarkers include KRAS mutations, B-type Raf kinase (BRAF) mutation, mesenchymal-epithelial transition factor (MET) amplification and Excision repair cross-complementing group 1 (ERCC1) can be used to see whether there are any genetic mutations that lead to lung cancer. Treatment of lung cancer with chemotherapy can be done using tyrosine kinase inhibitors and monoclonal antibodies.

Keywords: lung cancer, DNA mutation, EGFR, KRAS, BRAF, MET, tyrosine kinase

 


Full Text:

PDF

References


Todaro GJ, DeLarco JE, Cohen S. Transformation by Murine and Feline Sarcoma Viruses Specifically Blocks Binding of Epidermal Growth Factor to Cells. Nature 1976; 264: 26-31. CrossRef

Herbst RS, Heymach JV, Lippman SM. Lung Cancer. N Engl J Med. 2008; 359: 1367-80. CrossRef

Yarden Y, Sliwkowski MX. Untangling The ErbB Signaling Network. Nat Rev Mol Cell Biol. 2001; 2(2): 127-37. CrossRef

Schlessinger J. Cell Signaling by Receptor Tyrosine Kinases. Cell. 2000; 103(2): 211-25. CrossRef

Hendarmin L, Sandra F, Nakao Y, Ohishi M, Nakamura N. TNFalpha played a role in induction of Akt and MAPK signals in ameloblastoma. Oral Oncol. 2005; 41(4): 375-82. CrossRef

Sandra F, Hendarmin L, Nakao Y, Nakamura N, Nakamura S. Inhibition of Akt and MAPK pathways elevated potential of TNFalpha in inducing apoptosis in ameloblastoma. Oral Oncol. 2006; 42(1): 39-45. CrossRef

Sandra F, Matsuki NA, Takeuchi H, Ikebe T, Kanematsu T, Ohishi M, Hirata M. TNF inhibited the apoptosis by activation of Akt serine/threonine kinase in the human head and neck squamous cell carcinoma. Cell Signal. 2002; 14(9): 771-8. CrossRef

Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000; 100(1): 57-70. CrossRef

Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An Allosteric Mechanism for Activation of The Kinase Domain of Epidermal Growth Factor Receptor. Cell. 2006; 125(6): 1137-49. CrossRef

Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, et al. Differential Constitutive Activation of The Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification. Cancer Res. 2007; 67(5): 2046-53. CrossRef

Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR Mutations in Non-Small-Cell Lung Cancer: Analysis of A Large Series of Cases and Development of A Rapid and Sensitive Method for Diagnostic Screening with Potential Implications on Pharmacologic Treatment. J Clin Oncol. 2005; 23(4): 857-65. CrossRef

Hammerman PS, Janne PA, Johnson BE. Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res. 2009; 15(24): 7502-9. CrossRef

West H, Lilenbaum R, Harpole D, Wozniak A, Sequist L. Molecular Analysis-Based Treatment Strategies for The Management of Non-Small Cell Lung Cancer. J Thorac Oncol. 2009; 4 (9 Suppl 2): S1029-39; quiz S1041-2. CrossRef

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF Receptor Gene Mutations are Common in Lung Cancers from ‘Never Smokers’ and are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib. Proc Natl Acad Sci USA. 2004; 101(36): 13306-11. CrossRef

Knop CS. Lung cancer. In: Yarbro CH, Frogge MH, Goodman M, editors. Cancer Nursing: Principles and Practice. 6th ed. Boston: Jones & Bartlett; 2005. p.1379-1413. Link

Van Cleave JH, Cooley ME. Lung cancer. In: Varricchio CG, editor. A Cancer Sourcebook for Nurses. 8th ed. Sudbury: Jones & Bartlett; 2004. p.215-29. Link

Chen YB, Mu CY, Huang JA. Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Nonsmall Cell Lung Cancer: A 5-Year-Follow-Up Study. Tumori. 2012; 98(6): 751-5. CrossRef

D’Amato TA, Landreneau RJ, McKenna RJ, Santos RS, Parker RJ. Prevalence of In Vitro Extreme Chemotherapy Resistance in Resected Nonsmall-Cell Lung Cancer. Ann Thorac Surg. 2006; 81(2): 440-7. CrossRef

Eckardt JR, Bentsion DL, Lipatov ON, Polyakov IS, Mackintosh FR, Karlin DA, et al. Phase II Study of Picoplatin as Second-line Therapy for Patients with Small Cell Lung Cancer. J Clin Oncol. 2009; 27(12): 2046-51. CrossRef

Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, et al. A Phase II Study of ABT-751 in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2008; 3(6): 631-6. CrossRef

Verrils NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al. Microtubule Alterations and Mutations Induced by Desoxyepothilone B: Implications for Drug-Target Interaction. Chem Biol. 2003; 10(7): 597-607. CrossRef

Magnani N, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M. The βI/βIII-tubulin Isoforms and Their Complexes with Antimitotic Agents. FEBS J. 2006; 273(14): 3301-10. CrossRef

Jordan MA, Miller H, Ray A, Banerjee A, Manna T, Ni L, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol resistance recapitulates the phenotype of its origin has altered β-tubulin expression and is sensitive to ixabepilone. Presented at the 97th AACR Annual Meeting. Washington, District of Colombia, April 1-5; 2006 [abstract LB-280]. Link

Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence. J Clin Oncol. 2005; 23(11): 2513-20. CrossRef

Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, et al. The Landscape of EGFR Pathways and Personalized Management of Nonsmall-Cell Lung Cancer. Future Oncol. 2011; 7(4): 519-41. CrossRef

Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non- Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011; 29(15): 2121-7. CrossRef

Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib. N Engl J Med. 2011; 364(10): 947-55. CrossRef

Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy. Cancer Res. 1999; 59(6): 1236-43. Link

Brahmer J, Karen LR, Baas P, Crino L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 123-35. CrossRef

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002): A Randomised, Controlled, Phase 2 Trial. Lancet Oncol. 2015; 16: 908-18. CrossRef

Dela Cruz CS, Tanoue LT, Matthay RA. Lung Cancer: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2011; 32(4): 605-44. CrossRef

Rades D, Käsmann L, Schild SE, Janssen SA. Survival Score for Patients Receiving Palliative Irradiation for Locally Advanced Lung Cancer. Clin Lung Cancer. 2016; 17(6): 558-62. CrossRef

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19): 1823-33. CrossRef

Li X, Asmitananda T, Gao L, Gai D, Song Z, Zhang Y, et al. Biomarkers in the Lung Cancer Diagnosis: A Clinical Perspective. Neoplasma. 2012; 59(5): 500-7. CrossRef

Meiliana A, Dewi NM, Wijaya A. Cancer Immunotherapy: A Review. Indones Biomed J. 2016; 8: 1-20. CrossRef

Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, et al. Biomarkers For PD-1/PD-L1 Blockade Therapy in Non-Small-Cell Lung Cancer: Is PD-L1 Expression A Good Marker For Patient Selection?. Clin Lung Cancer. 2016; 17(5): 350-61. CrossRef

Meiliana A, Dewi NM, Wijaya A. Personalized Medicine: The Future of Health Care. Indones Biomed J. 2016; 8: 127-46. CrossRef

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009; 361: 947-57. CrossRef

Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, et al. Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of An Online Tumor Registry of Clinical Trials. Clin Cancer Res. 2009; 15(16): 5267-73. CrossRef

Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. PLoS Med. 2005; 2(1): e17. CrossRef

Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput Oncogene Mutation Profiling in Human Cancer. Nat Genet. 2007; 39(3): 347-51. CrossRef

Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of Somatic k-RAS Mutations as A Mechanism Associated with Resistance to EGFR-Targeted Agents: A Systematic Review and Meta-Analysis of Studies in Advanced Non-Small-Cell Lung Cancer and Metastatic Colorectal Cancer. Lancet Oncol. 2008; 9(10): 962-72. CrossRef

Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC, et al. KRAS Mutations and Resistance to EGFR-TKIs Treatment in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 22 Studies. Lung Cancer. 2011; 69(3): 272-8. CrossRef

Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib. J Clin Oncol. 2005; 23(25): 5900-9. CrossRef

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA Mutations on The Efficacy of Cetuximab Plus Chemotherapy in Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis. Lancet Oncol. 2010; 11(8): 753-62. CrossRef

Vakiani E, Solit DB. KRAS and BRAF: Drug Targets and Predictive Biomarkers. J Pathol. 2011; 223(2): 219-29. CrossRef

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of The BRAF Gene in Human Cancer. Nature. 2002; 417: 949-54. CrossRef

Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases. Clin Cancer Res. 2009; 15(14): 4554-60. CrossRef

Ladanyi M, Pao W. Lung Adenocarcinoma: Guiding EGFR-Targeted Therapy and Beyond. Mod Pathol. 2008; 21(Suppl 2): S16-S22. CrossRef

Seki T, Hagiya M, Shimonishi M, Nakamura T, Shimizu S. Organization of The Human Hepatocyte Growth Factor-Encoding Gene. Gene 1991; 102(2): 213-9. CrossRef

Nguyen KS, Kobayashi S, Costa DB. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway. Clin Lung Cancer. 2009; 10(4): 281-9. CrossRef

Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, et al. MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort. J Thorac Oncol. 2008; 3(4): 331-9. CrossRef

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science. 2007; 316(5827): 1039-43. CrossRef

Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer. Clin Cancer Res. 2009; 15(7): 2207-14. CrossRef

Gandara DR, Grimminger P, Mack PC, Lara PN Jr, Li T, Danenberg PV, et al. Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer. J Thorac Oncol. 2010; 5(12): 1933-8. CrossRef

Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, et al. Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites. J Thorac Oncol. 2009; 4(10): 1212-20. CrossRef

Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A, et al. Molecular Pathology of Lung Cancer: Key to Personalized Medicine. Mod Pathol. 2012; 25(3): 347-69. CrossRef




DOI: https://doi.org/10.21705/mcbs.v1i2.10

Copyright (c) 2017 Molecular and Cellular Biomedical Sciences

Indexed by:

                

                  

       

 

 Cell and BioPharmaceutical Institute